Renmin Hospital of Wuhan University, Wuhan 430060, P.R. China.
Int J Oncol. 2013 Sep;43(3):850-8. doi: 10.3892/ijo.2013.2007. Epub 2013 Jul 5.
CD59, belonging to membrane complement regulatory proteins (mCRPs), inhibits the cytolytic activity of complement and is overexpressed in many types of solid cancers. The aim of the present study was to detect the expression of CD59 in non-small cell lung cancer (NSCLC) and to investigate the relationship between decreased CD59 expression and tumorigenesis of NSCLC by transfecting recombinant retrovirus encoding shRNA targeting human CD59 into the human NSCLC cell line NCI-H157. CD59 expression in NSCLC was detected by immunocytochemistry (IHC). In the human NSCLC cell line NCI-H157, CD59 mRNA and protein expression suppressed with lentivirus-mediated RNAi was confirmed by using RT-PCR and western blotting, respectively. The proliferation and apoptosis of NCI-H157 cells was measured by using MTT assay and FACS. The resistance to complement cracking ability was detected by LDH assay. Caspase-3 expression in cells was assessed by IHC. Bcl-2 and Fas protein was determined by western blotting both in vitro and in vivo. CD59 is overexpressed in human NLCLC cancer. In NCI-H157 cells, lentivirus-mediated RNAi significantly reduced both CD59 mRNA and protein expression, which resulted in suppressing cell proliferation and increasing cell apoptosis. When incubated with fresh normal human serum (8%, v/v) for 1 h at 37˚C, the cell viability was decreased and cell apoptosis was increased in siCD59-infected NCI-H157 cells compared to siCD59-C-infected cells. Reduced CD59 expression led to increased expression of caspase-3 and Fas and decreased expression of Bcl-2. Furthermore, the nude mouse tumor graft weight was significantly decreased and survival rate was significantly increased in the siCD59 group. CD59 is overexpressed in human NLCLC. CD59 silencing in NSCLC cancer cells via retrovirus-mediated RNAi can enhance complement-mediated cell apoptosis, inhibiting the growth of NSCLC. CD59 may serve as a potential target for gene therapy in NSCLC.
CD59 属于膜补体调控蛋白(mCRP),可抑制补体的细胞溶解活性,在许多实体癌中过表达。本研究旨在检测非小细胞肺癌(NSCLC)中 CD59 的表达,并通过转染靶向人 CD59 的重组逆转录病毒,检测 CD59 表达降低与 NSCLC 发生之间的关系。采用免疫细胞化学(ICC)检测 NSCLC 中 CD59 的表达。采用 RT-PCR 和 Western blot 分别证实了慢病毒介导的 RNAi 对人 NSCLC 细胞系 NCI-H157 中 CD59 mRNA 和蛋白表达的抑制作用。采用 MTT 检测和 FACS 检测 NCI-H157 细胞的增殖和凋亡。采用 LDH 检测细胞对补体裂解能力的抵抗力。采用免疫组化(IHC)检测细胞中 caspase-3 的表达。采用 Western blot 检测体外和体内 Bcl-2 和 Fas 蛋白。CD59 在人 NLCLC 癌症中过表达。在 NCI-H157 细胞中,慢病毒介导的 RNAi 显著降低了 CD59 mRNA 和蛋白的表达,从而抑制了细胞增殖并增加了细胞凋亡。当在 37°C 下与新鲜正常人类血清(8%,v/v)孵育 1 小时时,与 siCD59-C 感染的细胞相比,siCD59 感染的 NCI-H157 细胞的细胞活力降低,细胞凋亡增加。CD59 表达降低导致 caspase-3 和 Fas 表达增加,Bcl-2 表达降低。此外,siCD59 组的裸鼠肿瘤移植重量显著降低,存活率显著提高。CD59 在人 NLCLC 中过表达。通过逆转录病毒介导的 RNAi 沉默 NSCLC 癌细胞中的 CD59 可以增强补体介导的细胞凋亡,抑制 NSCLC 的生长。CD59 可能成为 NSCLC 基因治疗的潜在靶点。